REVIEW article
Front. Soft Matter
Sec. Liquid Crystals
Volume 5 - 2025 | doi: 10.3389/frsfm.2025.1658466
Recent Advances in Lyotropic Liquid Crystal Nanoparticle Formulations for Drug Delivery Systems
Provisionally accepted- Sri Shanmugha College of Pharmacy, Sangagiri, India
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Lyotropic liquid crystalline (LLC) nanoparticles have gained significant attention as drug delivery systems owing to their unique self-assembly properties, biocompatibility, and ability to encapsulate both hydrophilic and hydrophobic drugs. This chapter explores recent advances in LLC formulations, focusing on their structural classification, physicochemical properties, and applications in controlled-drug delivery. Various mesophases, including lamellar, cubic, and hexagonal structures, have been discussed, highlighting their roles in controlled release. A comparative analysis reveals that cubic phases offer superior structural stability for sustained release, while hexagonal phases excel in high-viscosity applications, though their complex preparation limits scalability. In addition, key characterization techniques such as small-angle X-ray scattering, differential scanning calorimetry, and rheology are examined to offer insights into their stability and performance. Furthermore, the development of in situ gelling precursor systems and their applications in oral, transdermal, ocular, nasal, injectable, and periodontal drug delivery have been explored. The incorporation of stimuli-responsive materials into LLC systems enhances their adaptability to personalized medicine and advanced therapeutic strategies. Despite these advancements, challenges such as scalability, long-term stability, and clinical translation remain unresolved. This chapter highlights the potential of LLC nanoparticles to revolutionize modern drug delivery by improving bioavailability, therapeutic efficacy and patient compliance. Future research should focus on optimizing formulation strategies and exploring novel biomaterials to expand the clinical utility of LLC-based drug delivery systems.
Keywords: bioavailability, drug delivery system, lyotropic liquid crystals, liquid crystalline phase, nanoparticle
Received: 02 Jul 2025; Accepted: 25 Aug 2025.
Copyright: © 2025 Subash and Khute. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Sulekha Khute, Sri Shanmugha College of Pharmacy, Sangagiri, India
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.